Depomed Company Profile (NASDAQ:DEPO)

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

Depomed, Inc. (NASDAQ:DEPO) issued its earnings results on Monday, August, 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.09 by $0.52. The company had revenue of $100 million for the quarter, compared to analysts' expectations of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. Depomed's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.27 earnings per share. View Depomed's Earnings History.

Depomed is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Depomed.

9 analysts have issued 12 month price targets for Depomed's stock. Their forecasts range from $5.00 to $24.00. On average, they expect Depomed's share price to reach $13.22 in the next year. View Analyst Ratings for Depomed.

Here are some recent quotes from research analysts about Depomed stock:

• 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
• 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)

Some companies that are related to Depomed include U.S. Physical Therapy (USPH), AtriCure (ATRC), Revance Therapeutics (RVNC), Audentes Therapeutics (BOLD), CryoLife (CRY), LeMaitre Vascular (LMAT), Amphastar Pharmaceuticals (AMPH), Ignyta (RXDX), TG Therapeutics (TGTX), Alder BioPharmaceuticals (ALDR), AnaptysBio (ANAB), Civitas Solutions (CIVI), G1 THERAPEUTICS (GTHX), Aclaris Therapeutics (ACRS), Paratek Pharmaceuticals (PRTK), Achaogen (AKAO), Coherus BioSciences (CHRS) and WAVE Life Sciences (WVE).

Depomed's management team includes the folowing people:

• James P. Fogarty CPA, Chairman of the Board
• Arthur J. Higgins, President, Chief Executive Officer, Director
• August J. Moretti, Chief Financial Officer, Senior Vice President
• Matthew M. Gosling, Senior Vice President, General Counsel
• Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
• Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
• Karen A. Dawes, Independent Director
• Louis J. Lavigne Jr., Independent Director
• William T. McKee CPA, Independent Director
• Gavin T. Molinelli, Independent Director

Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include STARBOARD VALUE LP (8.70%), Vanguard Group Inc. (6.95%), State Street Corp (3.71%), Dimensional Fund Advisors LP (3.70%), Oak Ridge Investments LLC (3.69%) and Deltec Asset Management LLC (1.64%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Depomed's stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Vanguard Group Inc., Public Employees Retirement Association of Colorado, Capital Fund Management S.A., Cornerstone Capital Management Holdings LLC., Hussman Strategic Advisors Inc., OxFORD Asset Management LLP and Oak Ridge Investments LLC. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas. View Insider Buying and Selling for Depomed.

Depomed's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, ING Groep NV, State of Wisconsin Investment Board, Clark Estates Inc. NY, Marshall Wace North America L.P., Sivik Global Healthcare LLC, Systematic Financial Management LP and FMR LLC. View Insider Buying and Selling for Depomed.

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Depomed stock can currently be purchased for approximately $5.94.